Clinical trials
Completed trials in Indonesia with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
550 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 5 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 7 |
| 2014 | 8 |
| 2015 | 10 |
| 2016 | 15 |
| 2017 | 27 |
| 2018 | 28 |
| 2019 | 49 |
| 2020 | 45 |
| 2021 | 45 |
| 2022 | 37 |
| 2023 | 65 |
| 2024 | 71 |
| 2025 | 96 |
| 2026 | 27 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 550 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Indonesia University | 190 |
| Hasanuddin University | 32 |
| Universitas Padjadjaran | 31 |
| Gadjah Mada University | 23 |
| Universitas Sumatera Utara | 15 |
| Dr. Soetomo General Hospital | 11 |
| Dexa Medica Group | 10 |
| Udayana University | 10 |
| Dr Cipto Mangunkusumo General Hospital | 9 |
| Universitas Indonesia | 9 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Obesity | 20 |
| Diabetes Mellitus, Type 2 | 17 |
| Postoperative Pain | 15 |
| Anxiety Disorders | 14 |
| COVID-19 | 12 |
| Inflammation | 12 |
| Diabetes Mellitus | 11 |
| Tuberculosis | 9 |
| Malnutrition | 8 |
| Neoplasms | 8 |
Trials
Showing 1 to 25 of 550. Each trial links to its page on Pharma Observatory.
450 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.